IKZF1 Δ2-8/ALB gene deletions and MRD
There were no statistically significant differences between the two groups in the level of MRD at the 15th or 33rd day of induction chemotherapy or in the incidence of CNSL. In Group B, 34.5% of the patients were refractory/relapsed, which was significantly higher than Group A (34.5% vs. 13.3%, P =0.031). The mortality in Group B was significantly higher than Group A (17.2% vs. 2.2%, P =0.02), as shown in Table 1.